New horizons for gastric cancer: commentary

European Journal of Cancer, Supplement

Volumn 4, Issue 10, 2006, Pages 1-3

  Macdonald, John S ^a   Cervantes, Andrés ^b  

^a ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^b University Hospital of Valencia   (Spain)

Author keywords

Chemotherapy; Clinical trial; Docetaxel; Gastric cancer; Oxaliplatin

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; ANTHRACYCLINE; CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN; PLATINUM;

ADJUVANT CHEMOTHERAPY; ARTICLE; ASIA; CANCER INCIDENCE; CANCER SURGERY; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG EFFICACY; EASTERN EUROPE; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; HELICOBACTER INFECTION; HUMAN; LOWER ESOPHAGUS SPHINCTER; MONOTHERAPY; PRIORITY JOURNAL; SOUTH AMERICA; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33845483133     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6349(06)70001-5     Document Type: Article

References (27)

1. Kamangar F., Dores G., and Anderson W. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 (2006) 2137-2150
2. Gunderson L. Gastric cancer - patterns of relapse after surgical resection. Semin Radiat Oncol 12 (2002) 150-161
3. Earle C., and Maroun J. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 35 (1999) 1059-1064
4. Hermans J., Bonenkamp J., Boon M., et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 11 (1993) 1441-1447
5. Janunger K., Hafstrom L., and Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg 168 (2002) 597-608
6. Man E., Floriani I., Tinazzi A., et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol 11 (2000) 837-843
7. Panzini I., Gianni L., Fattori P., et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori 88 (2002) 21-27
8. Macdonald J., Smalley S., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345 (2001) 725-730
9. Macdonald JS, Smalley SR, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: Update of the results of Intergroup Study INT-0116 (SWOG 9008). ASCO Gastrointestinal Cancers Symposium, San Francisco, California, 22-24 January 2004 (Abstract 6).
10. Cunningham D., Allum W., Stenning S., et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355 (2006) 11-20
11. Wagner A., Grothe W., Haerting J., Kleber G., Grothey A., and Fleig W. Chemotherapy in advanced gastric cancer; a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24 (2006) 2903-2909
12. Wagner A., Grothe W., Behl S., et al. Chemotherapy for advanced gastric cancer. Coch Database Sys Rev 18 (2005) CD004064
13. Kim N., Park Y., Heo D., et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71 (1993) 3813-3818
14. Ohtsu A., Shimada Y., Shirao K., et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21 (2003) 54-59
15. Wils J., Klein H., Wagener D., et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9 (1991) 827-831
16. Waters J., Norman A., Cunningham D., et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80 (1999) 269-272
17. Vanhoefer U., Rougier P., Wilke H., et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18 (2000) 2648-2657
18. Cocconi G., Carlini P., Gamboni A., et al. Cisplatin, epirubicin, ieucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Ann Oncol 14 (2003) 1258-1263
19. Ross P., Nicolson M., Cunningham D., et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20 (2002) 1996-2004
20. Webb A., Cunningham D., Scarffe J., et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15 (1997) 261-267
21. Roth A., Maibach R., Falk S., et al. Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized phase II trial of the Swiss Group for Clinical cancer research (SAKK). J Clin Oncol 22 Suppl 14S (2004) 4020
22. Moiseyenko V., Ajani J., Tjulandin S., et al. Final results of randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) in patients (pts) with metastatic gastric adenocarcinoma. J Clin Oncol 23 Suppl 16S (2005) 4002
23. Van Cutsem E, Moiseyenko V, Tjulandin S, et al. Docetaxel when added to cisplatin-5-fluorouracil improves survival in advanced gastric cancer: a phase III trial. 7th World Congress on Gastro-intestinal Cancer, Barcelona, Spain, 15-18 June 2005 (Abstract O-012).
24. Aapro M., Cameron D., Pettengell R., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer (2006 Jun 5) [Epub ahead of print]
25. National Comprehensive Cancer Network. yeloid Growth Factors. Available at: www.nccn.org Accessed 11 July 2006
26. Schwartzberg L., Somerfield M., Somlo G., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24 (2006) 3187-3205
27. Cunningham D., Rao S., Starling N., et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol 24 Suppl 18S (2006) 182S (Abstract LBA4017)